Browse Publications
-
Alliance in the News, Feature ArticleFollowing Katz at FDA
February 11, 2013 | Steve Usdin, Washington Editor
Related topics: Alzheimer's Disease Drug Development PolicyOn February 11, 2013, Steve Usdin, Washington Editor of BioCentury, published an article in BioCentury The Bernstein Report on Business focused on the future of the FDA’s Division of Neurology Products following the expected retirement later this year of the current Division Director, Russell Katz, M.D. Representatives from the biopharmaceutical industry and the patient advocacy community were interviewed for this article, including Daniel Perry, President & CEO of the Alliance for Aging research and Chair of the ACT-AD Coalition. Mr. Perry highlighted ACT-AD’s positive relationship with Dr. Katz and expressed hope that Dr. Katz’s successor will approach the review of therapies for Alzheimer’s disease with similar openness and flexibility.
To read the BioCentury article, click here.
-
Get Mad ColumnHelping Stop a Devastating Disease: The ACT-AD Coalition Continues its Important Work in Alzheimer's
Winter 2013
Related topics: Access to Breakthroughs Alzheimer's Disease Drug Development Health PolicyAlzheimer's disease is a slow, dehumanizing, and fatal disease that strikes 1 in 8 people over the age of 65. While it's typically thought of as a disease that affects memory, it goes well beyond memory loss and eventually leads to death. -
Science in the SpotlightMuscle Loss & Aging: Combatting Sarcopenia and Lost Independence
Winter 2013 | Alliance for aging Research
Related topics: Access to Breakthroughs Aging Research Drug Development Geriatric Training HealthTypically, our muscles grow larger and stronger as we age. That is, until about the time we celebrate our 30th birthdays. That’s when most of us start down the other side of the hill and begin to gradually lose our muscle mass, strength, and function. While it’s usually not very noticeable in our 30s and 40s, the loss increases exponentially with age and tends to accelerate between the ages of 65 and 80.
This progressive loss of muscle mass is called sarcopenia, and it’s found to play a major role in the increased frailty, disability, and functional impairment that too often come with aging. While sarcopenia is a condition that is not uncommon with age, we don’t have to just sit back and accept it. There are things we can do to slow its progress, and current research promises to make that trip over-the-hill less traumatic. -
Alliance in the News, Alliance Views, VideoDan Perry on BioCentury This Week: Alzheimer's Research
In a March 18th interview with BioCentury This Week, Alliance for Aging Research President & CEO Daniel Perry shares his thoughts on U.S. funding of Alzheimer’s research. Perry also calls for the U.S. Food and Drug Administration to adopt biomarkers and other tools to detect and treat Alzheimer's disease earlier. -
Alliance in the News, Science in the SpotlightAlzheimer’s Biomarkers are Ready for Research
March 7, 2012
Related topics: Aging Research Alzheimer's Disease Brain Health Drug Development Drug Safety Health Medical Innovation Policy ResearchIn a March 1st interview, Dr. John Morris, co-chair of the Alzheimer's Disease Biomarker Expert Working Group (convened by the Alliance for Aging Research), explains what biomarkers are and how they will help research in the field of Alzheimer's disease and related dementia.
John C. Morris is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University. He also is the Director and Principal Investigator of the Alzheimer's Disease Research Center.
For More info on the promise of biomarkers in Alzheimer's, click here. -
Document, TestimonyAlliance President Makes Remarks at a Hearing on Prescription Drug User Fee Act Reauthorization
On October 24th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public. The PDUFA reauthorization process has historically been conducted through negotiations between the Agency and regulated industries, however the current round of negotiations allowed for patient groups to engage in monthly consultations with FDA representatives to enable all stakeholders to have an early voice in shaping the PDUFA V agreement.
-
Feature ArticleTreatments for Age-Related Macular Degeneration: Going Head to Head
Spring 2011 | Alliance for Aging Research
Related topics: Access to Breakthroughs Drug Development Drug Safety Health Medical Innovation Policy Quality of Care Research Vision LossExciting treatments make slowing and even restoring vision loss in wet age-related macular degeneration (wAMD) patients a reality. Two of the most frequently used treatments are currently in the spotlight as they go head-to-head in clinical trials comparing their effectiveness, and to some extent, exploring their costs. -
Get Mad ColumnCAN You Help Find a Cure?: Funding May Mean the Difference Between Life and Death
Spring 2010 | Alliance for Aging Research
Related topics: Access to Breakthroughs Drug Development Federal Funding Medical Innovation PolicyAfter a long fought battle over how best to structure meaningful health reform legislation, President Obama signed the Patient Protection and Affordable Care Act into law in March. Many media sources are reporting on the negative financial impact some health reform provisions might have on the country, but little attention has been focused on positive aspects of the bill that could make a real difference in the lives of many people suffering from, or who will face, serious and life-threatening illnesses. -
Get Mad ColumnThe Savings and Safety of Drug Importation
The president and Congress are embarking on a fervent campaign to reform our damaged health care system. Few would disagree that there is waste in our current system, and even fewer would disagree with the fact that we need to bring healthcare to the 46 million Americans who are currently uninsured. But, many in Washington and across the country disagree on how to go about financing the massive health care overhaul that lawmakers are now proposing. -
Get Mad ColumnEmpowering Patients with Information and Improving Care
No one can deny that our country’s health care spending is reaching an unmanageable level. In 2006 we spent over $2 trillion on health care and some experts predict that we’ll be spending twice that much by 2017. While you might assume that population growth is causing these increases—more people usually means more health care—we’re also seeing a rise in the amount of money that we spend on each person. -
Science in the SpotlightAll Roads Lead to...Sardinia!?
A drug now in clinical trials for treatment of type 2 diabetes could eventually be used to promote longevity by treating or preventing major age-related diseases. -
TestimonyStatement by Alliance for Aging Research Senior Director Debbie Zeldow before the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committe Meeting, concerning Eli Lilly and Company's bone formation drug, Forteo
My name is Deborah Zeldow, and I am the Senior Director of the Alliance for Aging Research. Thank you for the opportunity to come before this committee today to address the promising findings of Forteoâ„¢ (teriparatide, Lilly), Eli Lilly and Company's bone formation drug. -
ReportResearch At Risk
April 2000
Related topics: Access to Breakthroughs Drug Development Medical Innovation Quality of CareThis document is intended to increase understanding of the interplay between Medicare reform, prescription drug coverage, and continued progress of biomedical research in America.